7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

Authors :: M. D'Arcangelo
Lorenza Landi
Lisa Derosa
Annalisa Fontana
Daniele Santini
Guido Bocci
G. Minuti
Luca Galli
S. Bursi
Alfredo Falcone
Source :: European Journal of Cancer Supplements. 7:417
Publication Year :: 2009
Publisher :: Elsevier BV, 2009.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
Castration resistant
medicine.disease
First line treatment
Prostate cancer
Internal medicine
Pharmacodynamics
medicine
Celecoxib
business
Metronomic cyclophosphamide
medicine.drug

Tools